DW16011

Phase 3Small molecule

Daewon Pharmaceutical Co., Ltd.

DW16011 is one of 13 small molecule programs targeting Acute bronchitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute BronchitisActive, not recruiting

Acute BronchitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

34 competitors in Acute Bronchitis

#DrugCompanyPhaseTrials

Ceftin

PPhiladelphia Eye Associates

Azithromycin IV

1 3

Andrographolide Sulfonate

JJiangxi Qingfeng Pharmaceutical Co. Ltd.

Approved

1 4

Erdos

Daewoong Pharmaceutical Co. LTD.

Approved

1 5

Bronpass Tab.

HHanlim Pharm. Co., Ltd.

Approved

1 6

DW16011

Daewon Pharmaceutical Co., Ltd.

Phase 3

1 7

YHR2402

YYuhan Corporation

Phase 3

1 8

HL301

HHanlim Pharm. Co., Ltd.

Phase 2

2 9

Placabo

AAllergopharma GmbH & Co. KG

Phase 2

1 10

Atrovent

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute bronchitis1 trial

Clinical Trial to Evaluate the Efficacy and Safety of 'DW1601' in Acute Bronchitis

Unknown status· Daewon Pharmaceutical Co., Ltd. logo

Daewon Pharmaceutical Co., Ltd.·Phase 3·NCT04260555·204 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DW16011. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DW16011 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DW16011. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Daewon Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Daewon Pharmaceutical Co., Ltd.

DW16011

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute bronchitis1 trial

References

Drug Info

Quick Facts

Related News